FengHe Fund Management Pte. Ltd. Makes New $86.97 Million Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• FengHe Fund Management Pte. Ltd. bought a new position of 218,700 shares in Alnylam valued at approximately $86.97 million in Q4, making ALNY its 8th-largest holding and representing about 0.17% of the company.
• Analyst sentiment is broadly positive, with a MarketBeat consensus rating of Moderate Buy and a consensus price target of $472.78, while several firms (Oppenheimer, Raymond James, Bank of America) have issued buy/outperform ratings and price targets up to $500.
• Alnylam’s latest quarter missed estimates (EPS $1.25 vs. $1.43; revenue $1.10B vs. $1.16B), and insiders have sold 38,656 shares (~$12.37M) in the past 90 days, leaving insiders with roughly 0.86% ownership.

FengHe Fund Management Pte. Ltd. bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 218,700 shares of the biopharmaceutical company's stock, valued at approximately $86,966,000. Alnylam Pharmaceuticals accounts for approximately 4.9% of FengHe Fund Management Pte. Ltd.'s holdings, making the stock its 8th largest position. FengHe Fund Management Pte. Ltd. owned approximately 0.17% of Alnylam Pharmaceuticals as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ALNY. Root Financial Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $25,000. Salomon & Ludwin LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $27,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $29,000. Ameriflex Group Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $32,000. Finally, ORG Partners LLC raised its holdings in shares of Alnylam Pharmaceuticals by 70.2% in the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company's stock valued at $36,000 after purchasing an additional 33 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on ALNY shares. Raymond James Financial reiterated an "outperform" rating and issued a $472.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday, January 12th. Oppenheimer started coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, January 7th. They issued an "outperform" rating and a $500.00 price objective on the stock. Freedom Capital upgraded shares of Alnylam Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, February 17th. Bank of America reiterated a "buy" rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. Finally, Truist Financial lowered their price objective on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a "buy" rating on the stock in a report on Monday, April 13th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $472.78.

Insider Buying and Selling

In other news, insider Melissa Mclaughlin sold 2,286 shares of the business's stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $330.42, for a total value of $755,340.12. Following the completion of the sale, the insider owned 9,443 shares of the company's stock, valued at approximately $3,120,156.06. The trade was a 19.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the business's stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $319.73, for a total transaction of $528,193.96. Following the completion of the sale, the executive vice president directly owned 21,860 shares of the company's stock, valued at approximately $6,989,297.80. The trade was a 7.03% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 38,656 shares of company stock valued at $12,370,696 in the last 90 days. 0.86% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $308.51 on Tuesday. Alnylam Pharmaceuticals, Inc. has a one year low of $245.96 and a one year high of $495.55. The company has a market cap of $41.16 billion, a P/E ratio of 180.42 and a beta of 0.39. The firm's fifty day moving average price is $321.95 and its two-hundred day moving average price is $379.57. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.18). The company had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. Alnylam Pharmaceuticals's revenue for the quarter was up 84.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.65) earnings per share. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.75 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.